Metabolic reprogramming in cancer-associated fibroblasts: a central driver of breast cancer progression
Abstract
Globally, breast cancer is the most common malignancy in women, with both incidence and mortality rates showing an upward trend. The tumor microenvironment (TME) of breast cancer plays a crucial role in its initiation, progression, and metastasis. Cancer-associated fibroblasts (CAFs), as a key component of the TME, also play a vital role in tumor growth and metastasis. Furthermore, recent studies have found that metabolic reprogramming in CAFs is a key driver of their functional changes, involving significant alterations in CAF metabolic pathways. In addition to meeting their own metabolic demands, CAFs produce nutrients that sustain tumor cell growth. Furthermore, by secreting various cytokines and matrix components, they remodel the tumor microenvironment to promote progression and metastasis, thereby emerging as key drivers of breast cancer malignancy. Current research has elucidated the metabolic characteristics of CAFs in breast cancer, including alterations in glucose, amino acid, and lipid metabolism, and their impact on tumor biology. However, despite numerous studies exploring metabolic reprogramming in CAFs, the underlying specific mechanisms warrant further in-depth investigation. Therefore, this article will delve into CAFs and their metabolic reprogramming mechanisms in breast cancer, as well as their regulatory effects on tumor cells and other immune cells, aiming to provide new potential targets for the clinical treatment of breast cancer.
Related
- Immune cell metabolic reprogramming in pancreatic cancer: roles in tumor progression and therapeutic strategies
- A Full Spectrum Fibroblast Profiling Panel Reveals Phenotypic and Metabolic Heterogeneity of Cancer-Associated Fibroblasts at the Single-Cell Level
- Targeting O-GlcNAcylation in tumor-associated macrophages: from metabolic reprogramming to osteolytic niche formation in bone-invasive solid tumors
- Integration of bulk and single-cell transcriptomics via the Scissor algorithm reveals APOE-dependent cholesterol metabolic reprogramming in macrophages associated with osimertinib resistance in non-small cell lung cancer
- C5a drives central nervous system vasculitis in endothelial cells and fibroblasts via modulating the PI3K/ERK/CREB signaling pathways
BibTeX
@article{liu2026metabolic,
title = {{Metabolic reprogramming in cancer-associated fibroblasts: a central driver of breast cancer progression}},
author = {Qinyue Liu and Yaqian Liang and Fanglei Yang and Yun Hong and Yingying Shen},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1974557},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1974557},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Metabolic reprogramming in cancer-associated fibroblasts: a central driver of breast cancer progression
AU - Qinyue Liu
AU - Yaqian Liang
AU - Fanglei Yang
AU - Yun Hong
AU - Yingying Shen
PY - 2026
DA - 2026/11/09
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1974557
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1974557
AB - Globally, breast cancer is the most common malignancy in women, with both incidence and mortality rates showing an upward trend. The tumor microenvironment (TME) of breast cancer plays a crucial role in its initiation, progression, and metastasis. Cancer-associated fibroblasts (CAFs), as a key component of the TME, also play a vital role in tumor growth and metastasis. Furthermore, recent studies have found that metabolic reprogramming in CAFs is a key driver of their functional changes, involving significant alterations in CAF metabolic pathways. In addition to meeting their own metabolic demands, CAFs produce nutrients that sustain tumor cell growth. Furthermore, by secreting various cytokines and matrix components, they remodel the tumor microenvironment to promote progression and metastasis, thereby emerging as key drivers of breast cancer malignancy. Current research has elucidated the metabolic characteristics of CAFs in breast cancer, including alterations in glucose, amino acid, and lipid metabolism, and their impact on tumor biology. However, despite numerous studies exploring metabolic reprogramming in CAFs, the underlying specific mechanisms warrant further in-depth investigation. Therefore, this article will delve into CAFs and their metabolic reprogramming mechanisms in breast cancer, as well as their regulatory effects on tumor cells and other immune cells, aiming to provide new potential targets for the clinical treatment of breast cancer.
SN - 1664-3224
ER -